Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original article

Effectiveness of corticosteroids to treat coronavirus disease 2019 symptoms: A meta-analysis

Yiqian Zeng, Weizhong Zeng, Bihui Yang, Zhao Liu

* Department of Critical Care Medicine, Zhuzhou Central Hospital, Hunan, China
* Department of Hematology, Zhuzhou Central Hospital, Zhuzhou, Hunan, China

A R T I C L E  I N F O

Article history:
Received 7 September 2021
Accepted 9 March 2022
Available online 3 May 2022

Keywords:
Coronavirus disease 2019
Corticosteroids
Meta-analysis

A B S T R A C T

Objective: Currently, corticosteroids are widely used to treat coronavirus disease 2019 (COVID-19) symptoms. However, the therapeutic role of corticosteroids remains highly controversial. To that end, we aimed to assess the efficacy of corticosteroids in treating COVID-19 patients.

Method: We searched PubMed, Embase, and Cochrane Library to select suitable studies. Our primary study endpoint was all-cause mortality. The secondary study endpoint was the length of hospital stay.

Results: A total of 9 randomized controlled trials (RCTs) with 7907 patients were assessed. The pooled result indicated that corticosteroids treatment could significantly reduce all-cause mortality in patients with COVID-19 (RR = 0.88, 95% CI [0.82, 0.95], P < 0.002). When subgroup analyses were performed, we found that corticosteroids were associated with decreased all-cause mortality in severe COVID-19 patients (RR = 0.77, 95% CI [0.68, 0.88], P < 0.0001), however no obvious difference was observed in all-cause mortality of non-severe COVID-19 patients between the corticosteroid and control group (RR = 0.96, 95% CI [0.86, 1.06], P = 0.41), meanwhile, a low dose (RR = 0.89, 95% CI [0.82, 0.97], P = 0.007) of dexamethasone (RR = 0.9, 95% CI [0.83, 0.98], P = 0.01) with a long treatment course (RR = 0.89, 95% CI [0.82, 0.98], P = 0.02) was beneficial for all-cause mortality in COVID-19 patients. Additionally, we found that corticosteroids might be associated with a longer length of hospital stay in non-severe COVID-19 patients (MD = 3.83, 95% CI [1.11, 6.56], P = 0.006).

Conclusion: Our results showed that corticosteroid therapy was related to a reduction in all-cause mortality in severe COVID-19 patients. However, in patients with non-severe COVID-19, the use of corticosteroids did not decrease all-cause mortality and may prolong the duration of hospital stay. In addition, we revealed that a low dose of dexamethasone with a long treatment course could reduce all-cause mortality in COVID-19 patients.

© 2022 Elsevier España, S.L.U. All rights reserved.

Eficacia de los glucocorticoides en el tratamiento de los síntomas de la enfermedad por coronavirus 2019: un metaanálisis

R E S U M E N

Objetivo: Actualmente, los glucocorticoides se utilizan ampliamente para tratar los síntomas de la enfermedad por coronavirus 2019 (COVID-19). Sin embargo, el papel terapéutico de los glucocorticoides sigue siendo muy controvertido, por ello, nos propusimos evaluar su eficacia en el tratamiento de los pacientes con COVID-19.

Método: Se realizaron búsquedas en PubMed, Embase y Cochrane Library para seleccionar los estudios adecuados. El criterio de valoración principal del estudio fue la mortalidad por todas las causas. El criterio de valoración secundario del estudio fue la duración de la estancia en el hospital.

Palabras clave:
Enfermedad por coronavirus 2019
Glucocorticoides
Metaanálisis

* Corresponding author.
E-mail address: 372289013@qq.com (Z. Liu).
1 These authors contributed equally to this work.

https://doi.org/10.1016/j.medcli.2022.03.013
0025-7753/© 2022 Elsevier España, S.L.U. All rights reserved.
Results: Se evaluó un total de 9 ensayos controlados aleatorizados con 7.907 pacientes. En general, el tratamiento con glucocorticoides redujo la mortalidad por todas las causas en los pacientes con COVID-19 (RR = 0.88, IC 95% [0.82; 0.95], p = 0.002). Al realizar análisis de subgrupos, se observó que los glucocorticoides se asociaban a una disminución de la mortalidad por todas las causas en los pacientes con COVID-19 grave (RR = 0.77, IC 95% [0.68; 0.88], p < 0.0001), sin embargo no se observaron diferencias evidentes en la mortalidad por todas las causas de los pacientes con COVID-19 no grave entre el grupo de glucocorticoides y el de control (RR = 0.96, IC 95% [0.86; 1.06], p = 0.41), mientras que una dosis baja (RR = 0.89, IC 95% [0.82; 0.97], p = 0.007) de dexametasona (RR = 0.9, IC 95% [0.83; 0.98], p = 0.01) con un curso de tratamiento largo (RR = 0.89, IC 95% [0.82; 0.98], p = 0.02) fue beneficiosa para la mortalidad por todas las causas en los pacientes con COVID-19. Además, encontramos que los glucocorticoides podrían estar asociados con una mayor duración de la estancia hospitalaria en los pacientes con COVID-19 no grave (DM = 3.83, IC 95% [1.11; 6.56], p = 0.006).

Conclusion: Nuestros resultados mostraron que el tratamiento con glucocorticoides estaba relacionado con una reducción de la mortalidad por todas las causas en los pacientes con COVID-19 grave. Sin embargo, en los pacientes con COVID-19 no grave, el uso de glucocorticoides no disminuyó la mortalidad por todas las causas y puede prolongar la duración de la estancia hospitalaria. Además, descubrimos que una dosis baja de dexametasona con un curso de tratamiento largo podría reducir la mortalidad por todas las causas en los pacientes con COVID-19.

© 2022 Elsevier España, S.L.U. Todos los derechos reservados.

Introduction

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) appeared at the end of December 2019 and has since brought about an unprecedented challenge to public health worldwide.1 Reportedly, 20% of COVID-19 patients will progress to severe respiratory failure requiring intensive care.2-4 Severe cytokine and chemokine storms are believed to be involved in respiratory and multi-organ failure. Thus, immunosuppressive drugs such as corticosteroids have been widely used in the treatment of COVID-19 patients. Nevertheless, the role of corticosteroids in the management of COVID-19 remains a subject of controversy.

Recently, the RECOVERY trial reported a notable survival benefit of a daily low dosage of dexamethasone for up to 10 days in subjects with COVID-19 who were receiving oxygen therapy or mechanical ventilation.4 However, other clinical studies showed different results. The Metcovid trial found no benefit in the 28-day mortality of a low methylprednisolone dosage for 5 days in COVID-19 patients.7 Similarly, in the CAPE COD trial,5 compared with the placebo group, using low-dose hydrocortisone for 10 days or 8 days could not reduce mortality or the requirement for respiratory support. Additionally, a study by Jamaati et al.7 suggested that a 10-day high dosage of dexamethasone did not decrease mortality in patients with non-severe COVID-19 compared to the control group.

Previous meta-analyses of several RCTs mainly focused on the effect of corticosteroids treatment on severe COVID-19 patients. In this meta-analysis, we included more valuable RCTs to evaluate the efficacy of corticosteroids among not only severe but also non-severe COVID-19 patients.

Materials and methods

Search strategy and data sources

The present study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. Eligible RCTs were identified through a systematic search of PubMed, Embase and Cochrane Library from December 31, 2019 to March 31, 2021. The following search terms were used: (adrenal cortex hormone or corticosteroid or glucocorticoid or corticoid or steroid) and (COVID-19 or 2019 nCoV or coronavirus disease-19 or 2019 novel coronavirus disease or 2019-nCoV disease or coronavirus disease 2019 or SARS CoV-2 or nCov 2019). In addition, the references were manually searched to make the results more comprehensive. The work was done independently by two authors. A third investigator resolved all encountered disagreements.

Inclusion and exclusion criteria

Studies that met all of the following criteria were selected: (1) patients in each study were adults with laboratory-confirmed or clinically suspected COVID-19. (2) The participants were assigned to a corticosteroid group using corticosteroids plus standard care, and the control group received standard care without corticosteroids. We excluded conference abstracts, case reports, articles not in English and studies without full text or missing important data.

Our primary study endpoint was the all-cause mortality rate at the longest follow-up available. The secondary study endpoint was the length of stay in the hospital.

Data extraction

Two reviewers independently extracted data from the included studies. If there was any dispute, it was discussed or resolved by the third author. The following data were collected: first author, year of publication, study region, study design, inclusion criteria, type, dose, and duration of corticosteroid use, control intervention, outcome in each study, as well as the longest follow-up.

Quality assessment

The quality of each study was independently evaluated by two authors using the Cochrane Collaboration risk of bias, consisting of random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, selective reporting, and other biases.

Statistical analysis

The meta-analyses were performed using RevMan 5.4 software (The Nordic Cochrane Center, The Cochrane Collaboration, Copenhagen, Denmark). Dichotomous data were analyzed as the pooled relative risk (RR) with its 95% confidence interval (CI), while for continuous data, we calculated the mean difference (MD) and
the 95% CI. A P-value of <0.05 was considered statistically significant. Statistical heterogeneity between studies was estimated using statistic I². A random-effects model was used when either \( P < 0.1 \) or \( I^2 > 50\% \) defined significant heterogeneity; otherwise, the fixed-effects model was used.

For the primary study endpoint, subgroup analyses were carried out according to the severity of disease, corticosteroids dosage, type and treatment time. Severe COVID-19 patients were defined as those patients admitted to the Intensive Care Unit (ICU), and the remaining were non-severe. A low or high dosage was defined based on the cutoff values: dexamethasone 15 mg/day, hydrocortisone 400 mg/day, or equivalent methylprednisolone 80 mg/day.\(^8\) Besides, treatment duration was classified as short (<7 days) or long course (>7 days).

Results

Study selection

A total of 696 articles were obtained from our database search, 188 in PubMed, 297 in Embase, 211 in the Cochrane Library. After removing 151 duplicates and another 533 records by screening the title and abstract, there were 12 remaining full-text articles, among which 3 studies were removed due to non-randomized controlled trials. Ultimately, 9 trials\(^4,7,9–13\) were included. The literature screening workflow is shown in Fig. 1.

Study characteristics

The characteristics of included studies are summarized in Table 1. In total, 7907 patients from 9 studies were analyzed. Of the 9 studies, 2940 patients were treated with corticosteroids and 4967 were treated without corticosteroids. There were 5\(^4,6,9,10\) articles describing the use of corticosteroids in severe patients and another 5\(^4,7,11–13\) in non-severe patients. The corticosteroids utilized in the studies included hydrocortisone\(^6,9\), dexamethasone\(^4,7,10\) and methylprednisolone\(^5,15–13\).

Risk of bias

Results of the methodological quality assessment of included studies are presented in Fig. 2. As indicated, two trials\(^5,7\) have a low risk of bias, while the other seven trials\(^4,6,9–13\) were judged to have a high risk of bias.

All-cause mortality

All 9 trials reported data on all-cause mortality. There were 753 deaths among the 2940 patients in the corticosteroid group (25.6%) and 1363 deaths among the 4967 patients in the control group (27.4%). The pooled result indicated that corticosteroids treatment could significantly reduce all-cause mortality in patients with COVID-19 (RR = 0.88, 95% CI [0.82, 0.95], \( P = 0.002, I^2 = 28\% \)) (Fig. 3). When subgroup analyses were performed, we found that corticosteroid use was associated with decreased all-cause mortality in severe COVID-19 (RR = 0.77, 95% CI [0.68, 0.88], \( P < 0.0001, I^2 = 45\% \)) (Fig. 4). However, no obvious difference was observed in all-cause mortality of non-severe COVID-19 between the corticosteroid and control group (RR = 0.96, 95% CI [0.86, 1.06], \( P = 0.41, I^2 = 0\% \)) (Fig. 4). Interestingly, a low dose (RR = 0.89, 95% CI [0.82, 0.97], \( P = 0.007, I^2 = 0\% \)) or dexamethasone (RR = 0.9, 95% CI [0.83, 0.98], \( P = 0.01, I^2 = 0\% \)) with a long treatment course (RR = 0.89, 95% CI [0.82, 0.98], \( P = 0.02, I^2 = 5\% \)) could reduce all-cause mortality in COVID-19 patients (Figs. 5–7).

Duration of hospitalization

Two studies evaluated the length of hospital stay of non-severe COVID-19 patients; Data from the studies were pooled, and meta-analysis showed that corticosteroid use was significantly associated with longer length of hospital stay (MD = 3.83, 95% CI [1.11, 6.56], \( P = 0.006, I^2 = 0\% \)) (Fig. 8).

Discussion

SARS-CoV-2 is a highly transmissible virus that caused the greatest pandemic of the century. At present, we are looking for
| Study          | Study region                      | Study design       | Inclusion criteria                                                                                       | Dosage and duration of corticosteroids (n)                                                                 | Control intervention (n) | Primary outcome                                                                 | Longest follow-up |
|---------------|-----------------------------------|--------------------|--------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------------------|-------------------|
| Angus 2020    | Australia, Canada, France, Ireland, the Netherlands, New Zealand, the UK, the USA | Multicenter Open-label RCT | Aged at least 18 years confirmed or suspected COVID-19 admitted to ICU receiving respiratory or cardiovascular support | A fixed 7-day course of intravenous hydrocortisone (50 or 100 mg every 6 h) (n = 137) OR A shock-dependent course (50 mg every 6 h up to 28 d for shock patients) (n = 141) | Standard care (n = 101) | Respiratory and cardiovascular organ support-free days up to day 21 | 21 days          |
| Jeronimo 2020 | Brazil                            | Single center RCT  | Aged at least 18 years confirmed or suspected COVID-19 in use of oxygen therapy or under invasive mechanical ventilation | Methylprednisolone 1 mg/kg/d for 5 d (n = 194)                                                              | Standard care (n = 194) | 28-day mortality                                                                 | 28 days           |
| Dequin 2020   | France                            | Multicenter Double-blind RCT | Aged at least 18 years confirmed or suspected COVID-19 admitted to ICU with acute respiratory failure | Hydrocortisone 200 mg/d for 7 d, then 100 mg/d for 4 d and 50 mg/d for 3 d; if symptoms improved by day 4, then followed with hydrocortisone 100 mg/d for 2 d and 50 mg/d for 2 d (n = 76) | Standard care (n = 73) | Death or persistent respiratory support on 21 d                              | 21 days          |
| Edalatifard 2020 | Iran                       | Multicenter Single-blind RCT | Aged at least 18 years confirmed COVID-19 receiving oxygen therapy but not intubation or ventilation | Methylprednisolone 250 mg/d for 3 d (n = 34)                                                                | Standard care (n = 28) | Time to clinical improvement and hospital discharge or death                  | Until clinical improvement and hospital discharge or death |
| Tomazini 2020 | Brazil                            | Multicenter Open-label RCT | Aged at least 18 years confirmed or suspected COVID-19 receiving mechanical ventilation for ARDS | Dexamethasone 20 mg/d for 5 d, then 10 mg/d for 5 d or until ICU discharge (n = 151)                        | Standard care (n = 148) | Ventilator-free days at 28 d                                                  | 28 days           |
| Corral 2021   | Spain                             | Multicenter Open-label RCT | Aged at least 18 years confirmed COVID-19, not intubated or ventilated | Methylprednisolone 80 mg/d for 3 d, then 40 mg/d for 3 d (n = 35)                                            | Standard care (n = 29) | A composite of death, ICU admission, or requirement of noninvasive ventilation | Until composite endpoint happened |
| Horby 2021    | UK                                | Multicenter Open-label RCT | Confirmed or suspected COVID-19                                                                 | Oral or intravenous dexamethasone 6 mg/d for up to 10 d (or until hospital discharge if sooner) (n = 2104) | Standard care (n = 4321) | All-cause mortality within 28 d after randomization                           | 28 days           |
| Tang 2021     | China                             | Multicenter Single-blind RCT | Aged at least 18 years confirmed COVID-19 admitted to general wards less than 72 h | Methylprednisolone 1 mg/kg/d for 7 d (n = 43)                                                              | Standard care (n = 43) | Incidence of clinical deterioration 14 days after randomization               | 14 days           |
| Jamaati 2021  | Iran                              | Single center RCT    | Aged at least 18 years confirmed COVID-19 (PaO2/FiO2) between 100 and 300 mmHg | Dexamethasone 20 mg/d for 5 d, then 10 mg/d for 5 d (n = 25)                                                | Standard care (n = 25) | Need for invasive mechanical ventilation and death rate                        | 28 days           |
effective treatments to control this deadly and evolving disease. In this meta-analysis, we have assessed the effect of corticosteroids in COVID-19 patients. Corticosteroids therapy could significantly reduce all-cause mortality in patients with COVID-19. When subgroup analysis was performed according to disease severity, we found that corticosteroid use was associated with a decreased all-cause mortality in severe COVID-19, but not in patients with non-severe COVID-19. Moreover, we performed other subgroup analyses according to the dosage, type and treatment duration of corticosteroids. The pooled results suggested that a low dosage and long-term use of dexamethasone could reduce all-cause mortality in COVID-19 patients. Finally, we also concluded that corticosteroid use might be associated with a longer length of hospital stay in non-severe COVID-19 patients.

COVID-19-related respiratory or multi-organ failure might be due to an excessive immune response that damages pulmonary alveoli, leading to severe cytokine and chemokine storms with systemic effects. To dampen the inflammatory dysfunction, the administration of corticosteroids has attracted significant attention. In the past, corticosteroids have been used extensively in acute respiratory distress syndrome (ARDS), caused by SARS-CoV or Middle East respiratory syndrome (MERS)-CoV. Nevertheless, there is no consensus that corticosteroid administration is helpful for COVID-19 patients, considering the possibility of delayed...
Y. Zeng, W. Zeng, B. Yang et al.  
Medicina Clinica 159 (2022) 575–583

viral clearance, increased secondary infections or severe adverse events.

Previous meta-analytical studies have evaluated the role of corticosteroids in COVID-19 patients and reached mixed conclusions. A meta-analysis written by Lu et al.17 addressing the impact of corticosteroids in adults and children with coronavirus diseases (MERS, SARS, and COVID-19) included five studies available for COVID-19 indicating that corticosteroid use did not reduce mortality and might instead prolong the duration of hospital stay in adults with COVID-19. Similarly, another meta-analysis18 reviewed 5249 patients from 1 randomized clinical trial and 10 cohort involving coronavirus-related diseases caused by SARS-CoV-2, SARS-CoV, and MERS-CoV. Of the 5249 patients, 1426 were COVID-19 patients. Taking everything into account, corticosteroids use in patients affected by coronavirus diseases delayed virus clearing, failed to improve survival. Notably, SARS, MERS and COVID-19 are phenotypically heterogeneous despite their close virus phylogeny19 and may pose significant selection bias, collectively reducing the quality of the conclusion. Contrary to previous results, a prospective meta-analysis20 published in JAMA concluded that corticosteroids were associated with lower 28-day all-cause mortality in critically ill patients with COVID-19. Subsequently, Ma et al.21 conducted a

| Study or Subgroup | Corticosteroids | Control | Total | Weight | M-H, Fixed, 95% CI | M-H, Random, 95% CI |
|-------------------|----------------|---------|-------|--------|-------------------|-------------------|
| Angus 2020        | 78             | 278     | 33    | 101    | 5.4%              | 0.86 [0.61, 1.20]  |
| Dequin 2020       | 11             | 76      | 20    | 73     | 2.3%              | 0.53 [0.27, 1.02]  |
| Horby 2021        | 95             | 324     | 283   | 682    | 20.4%             | 0.71 [0.58, 0.86]  |
| Tomazini 2020     | 85             | 151     | 91    | 148    | 10.3%             | 0.92 [0.76, 1.11]  |
| Subtotal (95% CI) | 829            | 1005    | 38.4% |        | 0.77 [0.68, 0.85]  |
| Total events      | 269            | 427     |       |        |                   |                   |
| Heterogeneity: Ch² = 5.49, df = 3 (P = 0.14); P = 45%  
Test for overall effect: Z = 3.96 (P < 0.0001) |

| Non-ICU           |                |         |       |        |                   |                   |
| Corral 2021       | 7              | 35      | 5     | 29     | 0.6%              | 1.16 [0.41, 3.27]  |
| Horby 2021        | 387            | 1780    | 827   | 3638   | 60.8%             | 0.96 [0.86, 1.06]  |
| Tang 2021         | 0              | 43      | 1     | 43     | 0.2%              | 0.33 [0.01, 7.96]  |
| Subtotal (95% CI) | 1858           | 3710    | 61.6% |        | 0.98 [0.86, 1.06]  |
| Total events      | 394            | 833     |       |        |                   |                   |
| Heterogeneity: Ch² = 0.56, df = 2 (P = 0.76); P = 0%  
Test for overall effect: Z = 0.82 (P = 0.41) |

| Total (95% CI)    | 2687           | 4715    | 100.0%|        | 0.89 [0.82, 0.96]  |
| Total events      | 663            | 1280    |       |        |                   |                   |
| Heterogeneity: Ch² = 10.41, df = 6 (P = 0.11); P = 42%  
Test for overall effect: Z = 2.89 (P = 0.004)  
Test for subgroup differences: Ch² = 6.32, df = 1 (P = 0.01), P = 84.2% |

Fig. 4. Subgroup analysis for all-cause mortality according to the severity of COVID-19.

| Study or Subgroup | Corticosteroids | Control | Total | Weight | M-H, Random, 95% CI | M-H, Random, 95% CI |
|-------------------|----------------|---------|-------|--------|-------------------|-------------------|
| Edalatifar 2020   | 2              | 34      | 12    | 28     | 0.8%              | 0.14 [0.03, 0.56]  |
| Jamalei 2021      | 16             | 25      | 15    | 25     | 7.1%              | 1.07 [0.89, 1.65]  |
| Tomazini 2020     | 86             | 151     | 91    | 148    | 22.8%             | 0.92 [0.76, 1.11]  |
| Subtotal (95% CI) | 210            | 201     | 30.6% |        | 0.77 [0.44, 1.36]  |
| Total events      | 103            | 118     |       |        |                   |                   |
| Heterogeneity: Tau² = 0.16; Ch² = 8.07, df = 2 (P = 0.02); P = 75%  
Test for overall effect: Z = 0.90 (P = 0.37) |

| Low dose          |                |         |       |        |                   |                   |
| Angus 2020        | 78             | 278     | 33    | 101    | 10.7%             | 0.86 [0.61, 1.20]  |
| Corral 2021       | 7              | 35      | 5     | 29     | 1.4%              | 1.16 [0.41, 3.27]  |
| Dequin 2020       | 11             | 76      | 20    | 73     | 3.3%              | 0.43 [0.27, 1.02]  |
| Horby 2021        | 482            | 2104    | 1110  | 4321   | 37.8%             | 0.89 [0.81, 0.98]  |
| Jorionimo 2020    | 72             | 194     | 76    | 199    | 16.0%             | 0.97 [0.75, 1.29]  |
| Tang 2021         | 0              | 43      | 1     | 43     | 0.2%              | 0.33 [0.01, 7.96]  |
| Subtotal (95% CI) | 2730           | 4766    | 69.4% |        | 0.89 [0.62, 0.97]  |
| Total events      | 650            | 1245    |       |        |                   |                   |
| Heterogeneity: Tau² = 0.00; Ch² = 3.51, df = 5 (P = 0.62); P = 0%  
Test for overall effect: Z = 2.69 (P = 0.007) |

| Total (95% CI)    | 2940           | 4967    | 100.0%|        | 0.89 [0.79, 1.01]  |
| Total events      | 753            | 1383    |       |        |                   |                   |
| Heterogeneity: Tau² = 0.01; Ch² = 11.08, df = 8 (P = 0.20); P = 28%  
Test for overall effect: Z = 1.82 (P = 0.07)  
Test for subgroup differences: Ch² = 0.25, df = 1 (P = 0.62), P = 0% |

Fig. 5. Subgroup analysis for all-cause mortality according to the corticosteroid dosage.
meta-analysis of 7 RCTs that showed decreased all-cause mortality in severe COVID-19 patients following corticosteroid treatment. These two meta-analyses mainly focused on the effect of corticosteroid treatment on severe COVID-19 patients only and did not include non-severe COVID-19 patients.

The results of our meta-analysis show that corticosteroids could reduce all-cause mortality in COVID-19 patients. Subsequently, subgroup analyses for mortality stratified by severity of disease, corticosteroid dosage, type and treatment duration were performed in this meta-analysis. Corticosteroid use was associated
with decreased all-cause mortality in severe COVID-19 (RR = 0.77, 95% CI [0.68, 0.88], P < 0.0001, I^2 = 45%), but not in non-severe COVID-19 patients (RR = 0.96, 95% CI [0.86, 1.06], P = 0.41, I^2 = 0%). Survival benefit was observed with a low dosage (RR = 0.89, 95% CI [0.82, 0.97], P = 0.007, I^2 = 0%) and long treatment course (RR = 0.89, 95% CI [0.82, 0.98], P = 0.02, I^2 = 5%) of dexamethasone (RR = 0.9, 95% CI [0.83, 0.98], P = 0.01, I^2 = 0%) in COVID-19 patients. Furthermore, our findings showed that corticosteroid use in non-severe COVID-19 patients might be related to a lengthier hospital stay (MD = 3.83, 95% CI [1.11, 6.56], P = 0.006, I^2 = 0%). In non-severe COVID-19 people, an effective immune response with neutralizing antibodies promotes viral clearance and a short-lived inflammatory response. However, the immune response in patients with severe SARS-CoV-2 infection is quite strong, often resulting in ARDS or multi-organ dysfunction. Corticosteroids can reduce capillary dilation, inflammatory cell exudation, leukocyte infiltration, and phagocytosis in the early phase of inflammation, and also inhibit the excessive proliferation of capillaries and fibroblasts in the late stage. In conjunction with our results, treatment with corticosteroids appeared to be more beneficial in severe COVID-19. Moreover, the most effective type of corticosteroid treatment is another concern that needs to be addressed. In our study, dexamethasone could reduce all-cause mortality in COVID-19 patients, while a recent RCT demonstrated that methylprednisolone treatment was more beneficial than dexamethasone in COVID-19 treatment. Therefore, there is an urgent need for more RCTs to confirm and validate previous findings.

Limitations

Nevertheless, this meta-analysis has several limitations. Firstly, the study contained some high-quality RCTs, but the sample size of patients was dominated by the RECOVERY trial. Secondly, both severe and non-severe COVID-19 patients were included in our research, which might increase the overall heterogeneity. Thirdly, there was no unified standard for the type, time and dosage of corticosteroids used in the various studies. Fourthly, due to the limited data, we could not provide a meta-analysis on other outcomes such as organ support-free days, length of ICU stay, or duration of virus shedding. Lastly, some studies presented the data for continuous variables as the median and interquartile range (IQR), and we had to convert to mean and standard deviation.

Conclusions

The present meta-analysis revealed that corticosteroid therapy was related to reduced all-cause mortality in severe COVID-19 patients. However, in patients with non-severe COVID-19, the use of corticosteroids did not decrease the all-cause mortality and might instead prolong the duration of hospital stay. More importantly, we uncovered that extended use of low-dose dexamethasone could reduce all-cause mortality in COVID-19 patients. Nevertheless, more RCTs are needed to substantiate our conclusions.

Author contributions

YQZ, WZZ, and BHY searched databases and performed analysis. YQZ and WZZ wrote the manuscript. ZL and BHY designed the study and revised the manuscript. All authors read and approved the final manuscript.

Funding

This research received no external funding.

Conflicts of interest

The authors declare no conflict of interest.

References

1. Phelan AL, Katz R, Gostin LO. The novel coronavirus originating in Wuhan, China: challenges for global health governance. JAMA. 2020;323:709–10.
2. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019 (COVID-19). J Clin Invest. 2020;130:2620–9.
3. Zhang W, Zhao Y, Zhang F, Wang Q, Li T, Liu Z, et al. The use of anti-inflammatory drugs in the treatment of people with severe COVID-19 (COVID-19): the perspectives of clinical immunologists from China. Clin Immunol. 2020;214:108393.
4. Horby P, Lim WS, Embserson JR, Mafham M, Bell JL, Linsell L, et al. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.
5. Jeronimo CMP, Farias MEL, Val FFA, Sampaio VS, Alexandre MAA, Melo GC, et al. Methylprednisolone as adjunctive therapy for patients hospitalized with coronavirus disease 2019 (COVID-19; Metcovid): a randomized, double-blind, phase IIb, Placebo-controlled trial. Clin Infect Dis. 2021;72:e673–81.
6. Dequin PF, Heming N, Meziani F, Plantefèvre G, Voiriot G, Badié J, et al. Effect of hydrocortisone on 21-day mortality or respiratory support among critically ill patients with COVID-19: a randomized clinical trial. JAMA. 2020;324:1296–306.
7. Jamaati H, Hashemian SF, Farzaneh B, Malekmohammad M, Tabarsi P, Marjani M, et al. No clinical benefit of high dose corticosteroid administration in patients with COVID-19: a preliminary report of a randomized clinical trial. Eur J Pharmacol. 2021;897:173947.
8. Annane D, Pastores SM, Rochberg W, Arit W, Balk RA, Beishuizen A, et al. Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (Part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM). Intensive Care Med. 2017;43:1751–63.
9. Angus DC, Derde L, Al-Beidh F, Annane D, Arabi Y, Beane A, et al. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324:1317–29.
10. Tomazzini BM, Maia JS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDER randomized clinical trial. JAMA. 2020;324:1307–16.
11. Corral-Gudino I, Bahamonde A, Arnaiz-Reivillas F, Gómez-Barquero J, Abadía-Otero J, García-Ibarbia C, et al. Methylprednisolone in adults hospitalized with COVID-19 pneumonia: an open-label randomized trial (GLUCOCOVID). Wien Klin Wochenschr. 2021;133:303–11.
12. Edalatfard M, Alikhsan M, Salehi M, Naderi Z, Jamshidi A, Mostafaei S, et al. Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled trial. Eur Respir J. 2020;56.
13. Tang X, Feng YM, Ni JX, Zhang JY, Liu LM, Hu K, et al. Early use of corticosteroid may prolong SARS-CoV-2 shedding in non-intensive care unit patients with COVID-19 pneumonia: a multicenter, single-blind randomized control trial. Respiration. 2021;100:116–26.
14. Solinas C, Perra L, Aiole M, Miglioli E, Petrosillo N. A critical evaluation of glucocorticoids in the management of severe COVID-19. Cytokine Growth Factor Rev. 2020;54:8–23.
15. Arabi YM, Mandourah Y, Al-Hameed F, Sindi AA, Almekhlafi GA, Hussein MA, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197:757–67.
16. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006;3:e343.
17. Lu S, Zhou Q, Huang L, Shi Q, Zhao S, Wang Z, et al. Effectiveness and safety of glucocorticoids to treat COVID-19: a rapid review and meta-analysis. Ann Transl Med. 2020;8:627.
18. Li H, Chen C, Hu F, Wang J, Zhao Q, Gale RP, et al. Impact of corticosteroid therapy on outcomes of persons with SARS-CoV-2 SARS-CoV, or MERS-CoV infection: a systematic review and meta-analysis. Leukemia. 2020;34:1503–11.
19. Sterne JAC, Murthy S, Diaz JV, Slutsky AS, Villar J, Angus DC, et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA. 2020;324:1330–41.
20. Ma S, Xu C, Liu S, Sun X, Li R, Mao M, et al. Efficacy and safety of systematic corticosteroids among severe COVID-19 patients: a systematic review and meta-analysis of randomized controlled trials.Signal Transduct Target Ther. 2021;6:83.
21. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, et al. Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy. 2020;75:1564–81.